US EditionBristol Myers Squibb signs $11bn cancer drug deal with BioNTech
- Bristol Myers Squibb signed a global co-development and co-commercialization deal with BioNTech in 2025 to jointly develop an investigational bispecific antibody called BNT327.
- The deal followed BioNTech's progress in developing BNT327, a PD-L1xVEGF bispecific antibody now in Phase 3 trials for extensive-stage small cell lung cancer, with triple-negative breast cancer trials planned.
- Bristol Myers Squibb has committed an initial $1.5 billion to BioNTech, with additional guaranteed anniversary payments totaling up to $2 billion through 2028, and potential milestone payments reaching $7.6 billion, while both parties will equally share the costs and profits related to development and commercialization.
- BNT327 aims to succeed Opdivo, whose market exclusivity may expire in 2028, as Bristol Myers Squibb's CEO Christopher Boerner said the partnership will accelerate clinical trials and expand indications.
- The collaboration signals Bristol Myers Squibb's commitment to bispecific antibody immunotherapy as a potential new standard for solid tumors, while reflecting a costly investment in a competitive oncology market.
46 Articles
46 Articles
BioNTech Races to Cash In: $1.5 Billion Poured Into Cancer Drug for mRNA 'Collateral Damage'
BioNTech, the German biotech company that shot to global prominence during the COVID-19 pandemic through its mRNA vaccine partnership with Pfizer, has just signed a $1.5 billion deal with pharmaceutical giant Bristol Myers Squibb. The [...] The post BioNTech Races to Cash In: $1.5 Billion Poured Into Cancer Drug for mRNA ‘Collateral Damage’ appeared first on The People's Voice.
For the development of cancer therapies, the Mainz-based company is allied with the US company Bristol Myers Squibb. This could bring Biontech billions.
Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up
Could the world’s best-selling drug have competition on the way? American pharmaceutical giant Bristol Myers Squibb agreed Monday to pay up to $11.1 billion to partner with Germany’s BioNTech and co-develop its next-generation immunotherapy for cancer, which could compete directly with Merck & Co.’s breakthrough treatment Keytruda. Everybody Wants In At the heart of the deal is a relatively new drug technology called PD-1/VEGF bispecific antibod…
Coverage Details
Bias Distribution
- 71% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
